SG11201908578YA - Fc-optimized anti-cd25 for tumour specific cell depletion - Google Patents
Fc-optimized anti-cd25 for tumour specific cell depletionInfo
- Publication number
- SG11201908578YA SG11201908578YA SG11201908578YA SG11201908578YA SG 11201908578Y A SG11201908578Y A SG 11201908578YA SG 11201908578Y A SG11201908578Y A SG 11201908578YA SG 11201908578Y A SG11201908578Y A SG 11201908578YA
- Authority
- SG
- Singapore
- Prior art keywords
- stevenage
- london
- tusk
- catalyst
- building
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 5
- 241000581479 Apodichthys Species 0.000 abstract 2
- 241001609030 Brosme brosme Species 0.000 abstract 2
- 239000003054 catalyst Substances 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 239000002023 wood Substances 0.000 abstract 2
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 abstract 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 abstract 1
- 101000668058 Infectious salmon anemia virus (isolate Atlantic salmon/Norway/810/9/99) RNA-directed RNA polymerase catalytic subunit Proteins 0.000 abstract 1
- 108010002350 Interleukin-2 Proteins 0.000 abstract 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 abstract 1
- 241000451147 Lacon Species 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 238000003782 apoptosis assay Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 210000003289 regulatory T cell Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17161717 | 2017-03-17 | ||
| GBGB1710879.6A GB201710879D0 (en) | 2017-07-06 | 2017-07-06 | Methods and compounds for tumour-specific cell depletion |
| GBGB1714429.6A GB201714429D0 (en) | 2017-09-07 | 2017-09-07 | Compounds and methods for tumour-specific cell depletion |
| PCT/EP2018/056312 WO2018167104A1 (en) | 2017-03-17 | 2018-03-13 | Fc-optimized anti-cd25 for tumour specific cell depletion |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201908578YA true SG11201908578YA (en) | 2019-10-30 |
Family
ID=61655786
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201908578Y SG11201908578YA (en) | 2017-03-17 | 2018-03-13 | Fc-optimized anti-cd25 for tumour specific cell depletion |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US11879014B2 (enExample) |
| EP (1) | EP3596123B1 (enExample) |
| JP (2) | JP2020514363A (enExample) |
| KR (1) | KR20190130137A (enExample) |
| CN (1) | CN110869388B (enExample) |
| AU (1) | AU2018233976B2 (enExample) |
| BR (1) | BR112019017017A2 (enExample) |
| CA (1) | CA3056506A1 (enExample) |
| CL (1) | CL2019002624A1 (enExample) |
| CR (1) | CR20190477A (enExample) |
| DK (1) | DK3596123T3 (enExample) |
| ES (1) | ES2975063T3 (enExample) |
| FI (1) | FI3596123T3 (enExample) |
| HR (1) | HRP20240469T1 (enExample) |
| HU (1) | HUE065999T2 (enExample) |
| IL (1) | IL269081A (enExample) |
| LT (1) | LT3596123T (enExample) |
| MX (1) | MX2019010974A (enExample) |
| MY (1) | MY208220A (enExample) |
| NZ (1) | NZ756984A (enExample) |
| PE (1) | PE20191812A1 (enExample) |
| PL (1) | PL3596123T3 (enExample) |
| RS (1) | RS65351B1 (enExample) |
| SG (1) | SG11201908578YA (enExample) |
| SI (1) | SI3596123T1 (enExample) |
| WO (1) | WO2018167104A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017011592A1 (en) | 2015-07-13 | 2017-01-19 | Modular Genetics, Inc. | Generation of acyl alcohols |
| US11879014B2 (en) | 2017-03-17 | 2024-01-23 | Tusk Therapeutics Ltd. | Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody |
| CR20200466A (es) * | 2018-03-13 | 2020-11-11 | Tusk Therapeutics Ltd | Agentes anticuerpos anti-cd25 |
| JP7619941B2 (ja) * | 2018-11-14 | 2025-01-22 | アイバイオ， インク． | Ｃｄ２５抗体 |
| JP7695881B2 (ja) * | 2018-11-14 | 2025-06-19 | アイバイオ， インク． | 操作されたｃｄ２５ポリペプチドおよびその使用 |
| US20220251232A1 (en) * | 2019-05-20 | 2022-08-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Novel anti-cd25 antibodies |
| ES3037019T3 (en) * | 2019-06-10 | 2025-09-26 | Shandong Boan Biotechnology Co Ltd | Anti-cd25 antibody and application thereof |
| BR112022020521A2 (pt) | 2020-04-10 | 2023-03-07 | Rakuten Medical Inc | Compostos de corante ftalocianina, conjugados e métodos de uso dos mesmos |
| TW202144429A (zh) | 2020-05-14 | 2021-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 抗ｃｄ２５抗體、其抗原結合片段及其醫藥用途 |
| US11124568B1 (en) * | 2020-08-19 | 2021-09-21 | Vitruviae LLC | CD3/CD25 antibodies for neuro-immune diseases |
| WO2022106663A1 (en) * | 2020-11-20 | 2022-05-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-cd25 antibodies |
| EP4247497A1 (en) * | 2020-11-20 | 2023-09-27 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Anti-cd25 antibodies |
| US20240018248A1 (en) | 2020-12-02 | 2024-01-18 | Vib Vzw | An ltbr agonist in combination therapy against cancer |
| EP4288100A1 (en) * | 2021-02-02 | 2023-12-13 | Rakuten Medical, Inc. | Methods for local and systemic treatment of cancers, tumors and tumor cells |
| CA3209636A1 (en) | 2021-03-01 | 2022-09-09 | F. Hoffmann-La Roche Ag | Novel biomarkers and uses thereof |
| CN117916266A (zh) | 2021-09-02 | 2024-04-19 | 弗哈夫曼拉罗切有限公司 | 用于治疗aml的抗体 |
| CN119095621A (zh) | 2022-04-26 | 2024-12-06 | 弗哈夫曼拉罗切有限公司 | 用于治疗癌症的包括Fas轴拮抗剂和T-reg细胞消耗剂拮抗剂的联合疗法 |
| CN115181182B (zh) * | 2022-06-13 | 2024-03-29 | 南京融捷康生物科技有限公司 | 一种人源化的抗cd25的单域抗体及其应用 |
| WO2024006965A1 (en) * | 2022-06-30 | 2024-01-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Cd25-specific antibodies and uses thereof |
| WO2024006961A1 (en) | 2022-07-01 | 2024-01-04 | Neoleukin Therapeutics, Inc. | Neo-2/15 variants and uses thereof for preferentially stimulating t-regulatory cells |
| WO2024088987A1 (en) | 2022-10-26 | 2024-05-02 | F. Hoffmann-La Roche Ag | Combination therapy for the treatment of cancer |
| CN118240080A (zh) * | 2022-12-22 | 2024-06-25 | 深圳市福元生物科技有限公司 | 一种cd25单域抗体、人源化抗体、及制备方法 |
| EP4662238A1 (en) | 2023-02-06 | 2025-12-17 | F. Hoffmann-La Roche AG | Combination therapy and uses thereof |
| CN116087499B (zh) * | 2023-02-20 | 2023-10-31 | 深圳裕康医学检验实验室 | 一种癌样本的染色方法及试剂盒 |
| CN120314588B (zh) * | 2025-05-21 | 2025-10-17 | 成都蓉生药业有限责任公司 | 一种人免疫球蛋白抗体依赖性细胞介导的吞噬作用生物学活性的检测方法和检测试剂盒 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4208479A (en) | 1977-07-14 | 1980-06-17 | Syva Company | Label modified immunoassays |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| JPH05244982A (ja) | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化ｂ−ｂ１０ |
| NZ540555A (en) | 2002-11-15 | 2008-04-30 | Genmab As | Antibody therapeutics for treatingand/or preventing diseases associated with cells expressing CD25, including autoimmune diseases, inflammatory and hyperproliferative skin disorders |
| WO2004063355A2 (en) | 2003-01-10 | 2004-07-29 | Protein Design Labs, Inc. | Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of matastatic cancer |
| GB0409799D0 (en) | 2004-04-30 | 2004-06-09 | Isis Innovation | Method of generating improved immune response |
| GB0507696D0 (en) | 2005-04-15 | 2005-05-25 | Novartis Ag | Organic compounds |
| EP2032159B1 (en) | 2006-06-26 | 2015-01-07 | MacroGenics, Inc. | Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof |
| CA2656700A1 (en) | 2006-07-06 | 2008-01-10 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Compositions and methods for enhancing the efficacy of il-2 mediated immune responses |
| EP2423231A3 (en) | 2006-08-18 | 2012-05-30 | Novartis AG | PRLR-specific antibody and uses thereof |
| RU2391401C2 (ru) | 2008-02-12 | 2010-06-10 | Общество с ограниченной ответственностью "Лаборатория клеточного мониторинга" | СПОСОБ ПОЛУЧЕНИЯ ПОПУЛЯЦИИ CD4+CD25+Foxp3+ Т-ЛИМФОЦИТОВ ЧЕЛОВЕКА ex vivo, СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ |
| DK2356270T3 (da) | 2008-11-07 | 2016-12-12 | Fabrus Llc | Kombinatoriske antistofbiblioteker og anvendelser deraf |
| JP5746183B2 (ja) | 2009-09-22 | 2015-07-08 | プロビオゲン アーゲー | 特定のグリカン構造を含有する分子を生成する方法 |
| SG181690A1 (en) * | 2009-12-21 | 2012-07-30 | Regeneron Pharma | Humanized fcy r mice |
| AR079944A1 (es) | 2010-01-20 | 2012-02-29 | Boehringer Ingelheim Int | Anticuerpo neutralizante de la actividad de un anticoagulante |
| RU2598711C2 (ru) | 2010-07-22 | 2016-09-27 | Те Риджентс Оф Те Юниверсити Оф Калифорния | Антитело к противоопухолевому антигену и способы применения |
| CA2904532A1 (en) | 2013-03-15 | 2014-09-18 | Abbvie Biotechnology Ltd. | Anti-cd25 antibodies and their uses |
| CA2904527A1 (en) | 2013-03-15 | 2014-09-18 | Abbvie Biotechnology Ltd. | Anti-cd25 antibodies and their uses |
| DK2970486T3 (en) * | 2013-03-15 | 2018-08-06 | Xencor Inc | MODULATION OF T-CELLS WITH BISPECIFIC ANTIBODIES AND FC-FUSIONS |
| GB2526139A (en) | 2014-05-15 | 2015-11-18 | Biolnvent Internat Ab | Medicaments, uses and methods |
| US20170204154A1 (en) | 2016-01-20 | 2017-07-20 | Delinia, Inc. | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
| BR112018070636A2 (pt) | 2016-04-07 | 2019-02-05 | Cancer Research Technology Limited | método de tratamento de um sujeito humano que tem câncer, anticorpo, uso de um anticorpo, anticorpo para uso, combinação de um anticorpo, kit para uso no tratamento de câncer, composição farmacêutica, anticorpo biespecífico, método para tratamento de câncer, anticorpo biespecífico para uso e método de depleção de células t reguladoras em um tumor sólido em um sujeito |
| JP2019532996A (ja) | 2016-11-08 | 2019-11-14 | デリニア，インコーポレーテッド | 自己免疫疾患を処置するためのｉｌ−２変異体 |
| US11879014B2 (en) | 2017-03-17 | 2024-01-23 | Tusk Therapeutics Ltd. | Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody |
| MA51992A (fr) | 2018-03-13 | 2021-06-23 | Cancer Research Tech Ltd | Anticorps anti-cd25 pour la déplétion de cellules spécifiques d'une tumeur |
-
2018
- 2018-03-03 US US16/494,962 patent/US11879014B2/en active Active
- 2018-03-13 NZ NZ756984A patent/NZ756984A/en unknown
- 2018-03-13 PE PE2019001847A patent/PE20191812A1/es unknown
- 2018-03-13 MY MYPI2019005313A patent/MY208220A/en unknown
- 2018-03-13 MX MX2019010974A patent/MX2019010974A/es unknown
- 2018-03-13 HR HRP20240469TT patent/HRP20240469T1/hr unknown
- 2018-03-13 RS RS20240376A patent/RS65351B1/sr unknown
- 2018-03-13 WO PCT/EP2018/056312 patent/WO2018167104A1/en not_active Ceased
- 2018-03-13 DK DK18711313.9T patent/DK3596123T3/da active
- 2018-03-13 LT LTEPPCT/EP2018/056312T patent/LT3596123T/lt unknown
- 2018-03-13 AU AU2018233976A patent/AU2018233976B2/en active Active
- 2018-03-13 CR CR20190477A patent/CR20190477A/es unknown
- 2018-03-13 EP EP18711313.9A patent/EP3596123B1/en active Active
- 2018-03-13 FI FIEP18711313.9T patent/FI3596123T3/fi active
- 2018-03-13 PL PL18711313.9T patent/PL3596123T3/pl unknown
- 2018-03-13 BR BR112019017017A patent/BR112019017017A2/pt unknown
- 2018-03-13 JP JP2019550705A patent/JP2020514363A/ja active Pending
- 2018-03-13 SI SI201831085T patent/SI3596123T1/sl unknown
- 2018-03-13 KR KR1020197030283A patent/KR20190130137A/ko not_active Ceased
- 2018-03-13 HU HUE18711313A patent/HUE065999T2/hu unknown
- 2018-03-13 CA CA3056506A patent/CA3056506A1/en active Pending
- 2018-03-13 SG SG11201908578Y patent/SG11201908578YA/en unknown
- 2018-03-13 ES ES18711313T patent/ES2975063T3/es active Active
- 2018-03-13 CN CN201880018976.8A patent/CN110869388B/zh active Active
-
2019
- 2019-09-02 IL IL26908119A patent/IL269081A/en unknown
- 2019-09-13 CL CL2019002624A patent/CL2019002624A1/es unknown
-
2024
- 2024-01-25 JP JP2024009215A patent/JP2024050684A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| LT3596123T (lt) | 2024-03-25 |
| PL3596123T3 (pl) | 2024-06-24 |
| US20200010554A1 (en) | 2020-01-09 |
| CR20190477A (es) | 2020-01-07 |
| MX2019010974A (es) | 2020-08-03 |
| AU2018233976B2 (en) | 2025-03-20 |
| SI3596123T1 (sl) | 2024-05-31 |
| WO2018167104A1 (en) | 2018-09-20 |
| JP2020514363A (ja) | 2020-05-21 |
| PE20191812A1 (es) | 2019-12-26 |
| FI3596123T3 (fi) | 2024-04-17 |
| EP3596123A1 (en) | 2020-01-22 |
| IL269081A (en) | 2019-11-28 |
| BR112019017017A2 (pt) | 2020-04-14 |
| CA3056506A1 (en) | 2018-09-20 |
| AU2018233976A1 (en) | 2019-10-31 |
| KR20190130137A (ko) | 2019-11-21 |
| HUE065999T2 (hu) | 2024-06-28 |
| JP2024050684A (ja) | 2024-04-10 |
| CL2019002624A1 (es) | 2020-04-03 |
| HRP20240469T1 (hr) | 2024-07-19 |
| DK3596123T3 (da) | 2024-02-26 |
| CN110869388A (zh) | 2020-03-06 |
| MY208220A (en) | 2025-04-24 |
| EP3596123B1 (en) | 2024-01-10 |
| RS65351B1 (sr) | 2024-04-30 |
| ES2975063T3 (es) | 2024-07-03 |
| NZ756984A (en) | 2025-08-29 |
| US11879014B2 (en) | 2024-01-23 |
| CN110869388B (zh) | 2024-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201908578YA (en) | Fc-optimized anti-cd25 for tumour specific cell depletion | |
| SG11201901715UA (en) | Adenovirus armed with bispecific t cell engager (bite) | |
| SG11201903830TA (en) | Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies | |
| SG11201905699XA (en) | Anti-icos agonist antibodies and uses thereof | |
| SG11201810933QA (en) | Anti-c5 antibodies and uses thereof | |
| SG11201805136TA (en) | Group b adenovirus encoding an anti-tcr-complex antibody or fragment | |
| SG11201910143TA (en) | Combination of a cell therapy and an immunomodulatory compound | |
| SG11201900480YA (en) | Anti-tim-3 antibodies | |
| SG11201809710RA (en) | Genetically engineered cells and methods of making the same | |
| SG11201806905UA (en) | Peptides and combination of peptides for use in immunotherapy against non-small cell lung cancer and other cancers | |
| SG11201809064QA (en) | Chimeric neurotoxins | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201811148SA (en) | Cell penetrating peptide (cpp)-mediated ev loading | |
| SG11201903857UA (en) | Antibodies to pd-1 and uses thereof | |
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201807187XA (en) | Binding members to pd-l1 | |
| SG11201806496SA (en) | Antigen binding proteins that bind pd-l1 | |
| SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
| SG11201810801QA (en) | Brain delivery protein | |
| SG11201900132QA (en) | Selecting neoepitopes as disease-specific targets for therapy with enhanced efficacy | |
| SG11201907207UA (en) | Pharmaceutical combinations comprising an anti-ly75 antibody | |
| SG11202000484TA (en) | Cd38 antibody | |
| SG11201908980PA (en) | Treatment using chimeric receptor t cells incorporating optimized polyfunctional t cells | |
| SG11201901347UA (en) | Compositions and methods for cancer immunotherapy | |
| SG11201903400WA (en) | Anti-edb antibodies and antibody-drug conjugates |